Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Connective and Soft Tissue » Neoplasms, Adipose Tissue » Liposarcoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Connective and Soft Tissue » Sarcoma » Liposarcoma
Description
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed) MeSH
Hierarchy View
Subtype Terms (1)
Liposarcoma, Myxoid
12 drugs (9 approved, 3 experimental)
Approved Indicated Drugs (1)
Phase 3 Indicated Drugs (7)
Phase 2 Indicated Drugs (41)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (59)
Grupo Espanol de Investigacion en Sarcomas
Icahn School of Medicine at Mount Sinai
Infinity Pharmaceuticals, Inc.
Memorial Sloan-Kettering Cancer Center
National Institutes of Health (NIH)
Oregon Health and Science University
Organization Involved with Phase 1 Indications (10)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.